1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013. https://www.nice.org.uk/article/pmg9/ . Accessed 14 Sept 2017.
2. Stevenson M, et al. Mepolizumab for treating severe eosinophilic asthma: a single technology appraisal. School of Health and Related Research (ScHARR). Sheffield: NICE; 2016. https://www.nice.org.uk/guidance/ta431/documents/committee-papers . Accessed 14 Sept 2017.
3. National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. London: NICE; 2017. https://www.nice.org.uk/guidance/ta431 . Accessed 14 Sept 2017.
4. Boulet LP. Irreversible airway obstruction in asthma. Curr Allergy Asthma Rep. 2009;9(2):168–73.
5. British Thoracic Soceity/Scottish Intercollegiate Guidelines Network. SIGN 141 British guideline on the management of asthma. London: BTS/SIGN; 2014. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/ . Accessed 14 Sept 2017.